Lymphomas occurring specifically in HIV-infected patients: From pathogenesis to pathology

Seminars in Cancer Biology

Volumn 23, Issue 6 Part A, 2013, Pages 457-467

  Gloghini, Annunziata ^a   Dolcetti, Riccardo ^b   Carbone, Antonino ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

EBV; HIV associated lymphomas; HIV lymphoma; KSHV; Pathogenesis; Pathology

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B LYMPHOCYTE ACTIVATION; BURKITT LYMPHOMA; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTE FUNCTION; LYMPHOMA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTICENTRIC CASTLEMAN DISEASE; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; REVIEW; VIRUS IDENTIFICATION; VIRUS LATENCY;

EBV; HIV-ASSOCIATED LYMPHOMAS; HIV-LYMPHOMA; KSHV; PATHOGENESIS; PATHOLOGY;

BURKITT LYMPHOMA; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; SARCOMA, KAPOSI;

EID: 84887607258     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.08.004     Document Type: Review

References (95)

1. Raphael M., Said J., Borisch B., Cesarman E., Harris N.L. Lymphomas associated with HIV infection. World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008, 340-342. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
2. Carbone A., Cesarman E., Spina M., Gloghini A., Schulz T.F. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009, 113:1213-1224.
3. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
4. Grogg K.L., Miller R.F., Dogan A. HIV infection and lymphoma. J Clin Pathol 2007, 60:1365-1372.
5. Kirk O., Pedersen C., Cozzi-Lepri A., Antunes F., Miller V., Gatell J.M., et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001, 98:3406-3412.
6. Aboulafia D.M., Pantanowitz L., Dezube B.J. AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART. AIDS Read 2004, 14:605-617.
7. Van Baarle D., Nanlohy N.M., Otto S., Plunkett F.J., Fletcher J.M., Akbar A.N. Progressive telomere shortening of Epstein-Barr virus-specific memory T cells during HIV infection: contributor to exhaustion. J Infect Dis 2008, 198:1353-1357.
8. Martínez-Maza O., Breen E.C. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 2002, 14:528-532.
9. Pluda J.M., Venzon D.J., Tosato G., Lietzau J., Wyvill K., Nelson D.L., et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993, 11:1099-1107.
10. Breen E.C., Hussain S.K., Magpantay L., Jacobson L.P., Detels R., Rabkin C.S., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011, 20:1303-1314.
11. Landgren O., Goedert J.J., Rabkin C.S., Wilson W.H., Dunleavy K., Kyle R.A., et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010, 28:773-779.
12. Molyneux E.M., Rochford R., Griffin B., Newton R., Jackson G., Menon G., et al. Burkitt's lymphoma. Lancet 2012, 379(9822):1234-1244.
13. Capello D., Martini M., Gloghini A., Cerri M., Rasi S., Deambrogi C., et al. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica 2008, 93:1178-1185.
14. Siebert J.D., Ambinder R.F., Napoli V.M., Quintanilla-Martinez L., Banks P.M., Gulley M.L. Human immunodeficiency virus-associated Hodgkin's disease contains latent, not replicative, Epstein-Barr virus. Hum Pathol 1995, 26:1191-1195.
15. Carbone A., Gloghini A., Serraino D., Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009, 4:3-10.
16. Staal S.P., Ambinder R., Beschorner W.E., Hayward G.S., Mann R. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease. Am J Clin Pathol 1989, 91:1-5.
17. Mueller N., Mohar A., Evans A., Harris N.L., Comstock G.W., Jellum E., et al. Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma. Int J Cancer 1991, 49:387-393.
18. van Baarle D., Hovenkamp E., Callan M.F., Wolthers K.C., Kostense S., Tan L.C., et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001, 98:146-155.
19. Epeldegui M., Widney D.P., Martínez-Maza O. Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 2006, 18:444-448.
20. Dehee A., Asselot C., Piolot T., Jacomet C., Rozenbaum W., Vidaud M., et al. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol 2001, 65:543-552.
21. Piriou E.R., van Dort K., Nanlohy N.M., Miedema F., van Oers M.H., van Baarle D. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol 2004, 172:6931-6937.
22. Van Baarle D., Wolthers K.C., Hovenkamp E., Niesters H.G., Osterhaus A.D., Miedema F., et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 2002, 186:405-409.
23. Richard Y., Amiel C., Jeantils V., Mestivier D., Portier A., Dhello G., et al. Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus-infected patients before and after antiretroviral therapy. J Infect Dis 2010, 202:1424-1434.
24. Dolcetti R., Martorelli D., Dal Col J., Carbone A., Klein E. Viral antigens and cellular pathways interplay in the development of EBV-driven lymphomas. Seminars Cancer Biol 2013, 23:441-456.
25. Kaye K.M., Izumi K.M., Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993, 90:9150-9154.
26. Hong G.K., Kumar P., Wang L., Damania B., Gulley M.L., Delecluse H.J., et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005, 79:13984-13992.
27. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011, 85:165-177.
28. Guasparri I., Keller S.A., Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004, 199:993-1003.
29. Godfrey A., Anderson J., Papanastasiou A., Takeuchi Y., Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005, 105:2510-2518.
30. Moore P.S., Boshoff C., Weiss R.A., Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996, 274(5293):1739-1744.
31. Aoki Y., Jaffe E.S., Chang Y., Jones K., Teruya-Feldstein J., Moore P.S., et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999, 93:4034-4043.
32. Jones K.D., Aoki Y., Chang Y., Moore P.S., Yarchoan R., Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999, 94:2871-2879.
33. Chang Y., Moore P.S., Talbot S.J., Boshoff C.H., Zarkowska T., Godden-Kent D., et al. Cyclin encoded by KS herpesvirus. Nature 1996, 382(6590):410.
34. Sarek G., Järviluoma A., Ojala P.M. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood 2006, 107:725-732.
35. Järviluoma A., Child E.S., Sarek G., Sirimongkolkasem P., Peters G., Ojala P.M., et al. Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 2006, 26:2430-2440.
36. Friborg J., Kong W., Hottiger M.O., Nabel G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999, 402(6764):889-894.
37. Radkov S.A., Kellam P., Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene HRAS transforms primary rat cells. Nat Med 2000, 6:1121-1127.
38. Sarek G., Kurki S., Enbäck J., Iotzova G., Haas J., Laakkonen P., et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007, 117:1019-1028.
39. Liu J., Martin H.J., Liao G., Hayward S.D. The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol 2007, 81:10451-10459.
40. Bubman D., Guasparri I., Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 2007, 26:4979-4986.
41. Santag S., Jäger W., Karsten C.B., Kati S., Pietrek M., Steinemann D., et al. Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells. Oncogene 2012, [Epub ahead of print]. 10.1038/onc.2012.385.
42. Rivas C., Thlick A.E., Parravicini C., Moore P.S., Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001, 75:429-438.
43. Esteban M., García M.A., Domingo-Gil E., Arroyo J., Nombela C., Rivas C. The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. J Gen Virol 2003, 84(Pt 6):1463-1470.
44. Wies E., Mori Y., Hahn A., Kremmer E., Stürzl M., Fleckenstein B., et al. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008, 111:320-327.
45. Skalsky R.L., Samols M.A., Plaisance K.B., Boss I.W., Riva A., Lopez M.C., et al. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol 2007, 81:12836-12845.
46. Gottwein E., Mukherjee N., Sachse C., Frenzel C., Majoros W.H., Chi J.T., et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007, 450:1096-1099.
47. Lei X., Zhu Y., Jones T., Bai Z., Huang Y., Gao S.J. A Kaposi's sarcoma-associated herpesvirus microRNA and its variants target the transforming growth factor β pathway to promote cell survival. J Virol 2012, 86:11698-11711.
48. He B., Qiao X., Klasse P.J., Chiu A., Chadburn A., Knowles D.M., et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006, 176:3931-3941.
49. Martin G., Roy J., Barat C., Ouellet M., Gilbert C. Tremblay MJ.Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J Virol 2007, 81:5872-5881.
50. Imbeault M., Ouellet M., Giguère K., Bertin J., Bélanger D., Martin G., et al. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. J Virol 2011, 85:2189-2200.
51. Fiorentini S., Marini E., Caracciolo S., Caruso A. Functions of the HIV-1 matrix protein p17. New Microbiol 2006, 29:1-10.
52. Giagulli C., Marsico S., Magiera A.K., Bruno R., Caccuri F., Barone I., et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS ONE 2011, 6:e17831.
53. Popovic M., Tenner-Racz K., Pelser C., Stellbrink H.J., van Lunzen J., Lewis G., et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 2005, 102:14807-14812.
54. Ferry J.A. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist 2006, 11:375-383.
55. Carbone A., Gloghini A., Larocca L.M., Capello D., Pierconti F., Canzonieri V., et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001, 97:744-751.
56. Carbone A., Gloghini A., Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008, 13:577-585.
57. Carbone A., Tirelli U., Gloghini A., Volpe R., Boiocchi M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993, 11:1674-1681.
58. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens. Part B: Biological Agents/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, vol. 100 2012, IARC Press, Lyon.
59. Leucci E., Onnis A., Cocco M., De Falco G., Imperatore F., Giuseppina A., et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer 2010, 126:1316-1326.
60. Leucci E., Cocco M., Onnis A., De Falco G., van Cleef P., Bellan C., et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 2008, 216:440-450.
61. Klein U., Gloghini A., Gaidano G., Chadburn A., Cesarman E., Dalla-Favera R., et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003, 101:4115-4121.
62. Tarte K., De Vos J., Thykjaer T., Zhan F., Fiol G., Costes V., et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002, 100:1113-1122.
63. Tarte K., Zhan F., De Vos J., Klein B., Shaughnessy J. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003, 102:592-600.
64. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995, 332:1186-1191.
65. Nador R.G., Cesarman E., Chadburn A., Dawson D.B., Ansari M.Q., Sald J., et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the kaposi's sarcoma-associated herpes virus. Blood 1996, 88:645-656.
66. Carbone A., Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008, 140:13-24.
67. Carbone A., Cesarman E., Gloghini A., Drexler H.G. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS 2010, 24:479-490.
68. Gaidano G., Carbone A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. Adv Cancer Res 2001, 80:115-146.
69. Du M.Q., Bacon C.M., Isaacson P.G. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007, 60:1350-1357.
70. Schulz T.F. Epidemiology of kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. Adv Cancer Res 1999, 76:121-160.
71. Simonelli C., Spina M., Cinelli R., Talamini R., Tedeschi R., Gloghini A., et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003, 21:3948-3954.
72. Fan W., Bubman D., Chadburn A., Harrington W.J., Cesarman E., Knowles D.M. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 2005, 79:1244-1251.
73. Carbone A., Gloghini A.P.E.L HHV8-unrelated effusion lymphomas: classification and diagnosis. Cancer 2008, 114:225-227.
74. Kobayashi Y., Kamitsuji Y., Kuroda J., Tsunoda S., Uoshima N., Kimura S., et al. Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature. Acta Haematol 2007, 117:132-144.
75. Brimo F., Michel R.P., Khetani K., Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007, 111:224-233.
76. Katano H., Suda T., Morishita Y., Yamamoto K., Hoshino Y., Nakamura K., et al. Human herpesvirus 8-associated solid lymphomas that occur in AIDS patients take anaplastic large cell morphology. Mod Pathol 2000, 13:77-85.
77. Engels E.A., Pittaluga S., Whitby D., Rabkin C., Aoki Y., Jaffe E.S., et al. Immunoblastic lymphoma in persons with AIDS-associated kaposi's sarcoma: a role for kaposi's sarcoma-associated herpesvirus. Mod Pathol 2003, 16:424-429.
78. Chadburn A., Hyjek E., Mathew S., Cesarman E., Said J., Knowles D.M. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004, 28:1401-1416.
79. Carbone A., Gloghini A., Vaccher E., Cerri M., Gaidano G., Dalla-Favera R., et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005, 7:17-27.
80. Mate J.L., Navarro J.T., Ariza A., Ribera J.M., Castella E., Junca J., et al. Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma. Hum Pathol 2004, 35:632-635.
81. Navarro J.T., Ribera J.M., Junca J., Milla F. Anorectal lymphoma without effusion associated with human herpesvirus-8 and type 1 Epstein-Barr virus in an HIV-infected patient. Hum Pathol 2003, 34:630.
82. Pantanowitz L., Wu Z., Dezube B.J., Pihan G. Extracavitary primary effusion lymphoma of the anorectum. Clin Lymphoma Myeloma 2005, 6:149-152.
83. Fend F., Cabecadas J., Gaulard P., Jaffe E.S., Kluin P., Peterson L.A., et al. Early lesion in lymphoid neoplasia. J Hematopathol 2012, 5:169-199.
84. Dupin N., Diss T.L., Kellam P., Tulliez M., Du M.Q., Sicard D., et al. HHV-8 is associated with a plasmablastic variant of castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000, 95:1406-1412.
85. Isaacson P.G., Campo E., Harris N.L. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008, 258-259. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
86. Delecluse H.J., Anagnostopoulos I., Dallenbach F., Hummel M., Marafioti T., Schneider U., et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997, 89:1413-1420.
87. Stein H., Harris N.L., Campo E. Plasmablastic lymphoma. World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008, 256-257. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
88. Castillo J., Pantanowitz L., Dezube B.J. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008, 83:804-809.
89. Pantanowitz L., Dezube B.J. Editorial comment: plasmablastic lymphoma - a diagnostic and therapeutic puzzle. AIDS Read 2007, 17:448-449.
90. Rafaniello Raviele P., Pruneri G., Maiorano E. Plasmablastic lymphoma: a review. Oral Dis 2009, 15:38-45.
91. Riedel D.J., Gonzalez-Cuyar L.F., Zhao X.F., Redfield R.R., Gilliam B.L. Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008, 8:261-267.
92. Carbone A., Gaidano G., Gloghini A., Ferlito A., Rinaldo A., Stein H. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol 1999, 108:95-99.
93. Carbone A., Gloghini A., Gaidano G. Is plasmablastic lymphoma of the oral cavity an HHV-8-associated disease?. Am J Surg Pathol 2004, 28:1538-1540. [author reply 1540].
94. Colomo L., Loong F., Rives S., Pittaluga S., Martinez A., Lopez-Guillermo A., et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004, 28:736-747.
95. Teruya-Feldstein J. Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep 2005, 7:357-363.